Volume 4.38 | Oct 1

Pancreatic Cell News 4.38 October 1, 2013
Pancreatic Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
Activated Wnt Signaling in Stroma Contributes to Development of Pancreatic Mucinous Cystic Neoplasms
Scientists investigated the involvement of Wnt signaling in KRAS-mediated pancreatic tumorigenesis and development of mucinous cystic neoplasm (MCN) in mice, and Wnt activation in human MCN samples. Expression of Wnt1 in the pancreatic acinar cells and acinar cell progenitors of female mice led to development of unilocular or multilocular epithelial cysts in the pancreas body and tail, similar to MCN. [Gastroenterology] Abstract
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
PUBLICATIONS (Ranked by impact factor of the journal)

Intraislet SLIT-ROBO Signaling Is Required for Beta-Cell Survival and Potentiates Insulin Secretion
Scientists found SLIT1 and SLIT3 in both beta cells and alpha cells, whereas SLIT2 was predominantly expressed in beta cells. Slit-Roundabout receptor (ROBO)1 and ROBO2 receptors were detected in beta and alpha cells. Remarkably, even modest knockdown of Slit production resulted in significant beta-cell death, demonstrating a critical autocrine/paracrine survival role for this pathway. [Proc Natl Acad Sci USA] Abstract

SMAD2 Disruption in Mouse Pancreatic Beta Cells Leads to Islet Hyperplasia and Impaired Insulin Secretion Due to the Attenuation of ATP-Sensitive K+ Channel Activity
To identify distinct roles for the downstream components of the canonical TGF-β signaling pathway, a Cre-loxP system was used to disrupt SMAD2, an intracellular transducer of TGF-β signals, in pancreatic beta cells. [Diabetologia] Abstract

Defective Prolactin Signaling Impairs Pancreatic Beta Cell Development during the Perinatal Period
Researchers provide evidence that expansion of beta cell mass during both embryogenesis and the postnatal period is impaired in the prolactin receptor-/- mouse model. [Am J Physiol Endocrinol Metab] Abstract

Reprogramming of Pig Dermal Fibroblast into Insulin Secreting Cells by a Brief Exposure to 5-Aza-Cytidine
Pig dermal fibroblasts were exposed to DNA methyltransferase inhibitor 5-aza-cytidine for 18 hours. After a brief recovery period, fibroblasts were subjected to a three-step protocol for the induction of endocrine pancreatic differentiation that was completed after 42 days. [Stem Cells Rev] Abstract


Epithelial Splicing Regulatory Protein 1 Is a Favorable Prognostic Factor in Pancreatic Cancer that Attenuates Pancreatic Metastases
Increased epithelial splicing regulatory protein 1 (ESRP1) expression was associated with longer survival in comparison with low ESRP1 expression, and PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro, whereas ESRP1 small interference RNA-transfected KLM-1 cells exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. [Oncogene] Abstract

The Neurotrophic Factor Neurturin Contributes towards an Aggressive Cancer Cell Phenotype, Neuropathic Pain and Neuronal Plasticity in Pancreatic Cancer
The impact of neurotrophic factor neurturin (NRTN)/GFRα-2 on pancreatic cancer (PCa) cell (PCC) biology was investigated via exposure to hypoxia, MTT viability and Matrigel invasion assays in native and specific siRNA-silenced PCCs. PCa tissue and PCCs contained increased amounts of NRTN, which was suppressed under hypoxia. [Carcinogenesis] Abstract

Targeting Pancreatic Cancer with Magneto-Fluorescent Theranostic Gold Nanoshells
Researchers report a magneto-fluorescent theranostic nanocomplex targeted to neutrophil gelatinase-associated lipocalin (NGAL) for imaging and therapy of pancreatic cancer. Anti-NGAL-conjugated theranostic gold nanoshells specifically targeted pancreatic cancer cells in vitro and in vivo providing contrast for both near-infrared fluorescence and T2-weighted MRI with higher tumor contrast than can be obtained using long-circulating, but nontargeted, PEGylated nanoparticles. [Nanomedicine] Abstract

A Binuclear Complex Constituted by Diethyldithiocarbamate and Copper(I) Functions as a Proteasome Activity Inhibitor in Pancreatic Cancer Cultures and Xenografts
Researchers investigated the anticancer potential of this complex on pancreatic cancer and the possible mechanism. The results suggest that diethyldithiocarbamate-Cu(I) inhibit pancreatic cancer cell proliferation and proteasome activity in vitro and in vivo. [Toxicol Appl Pharmacol] Full Article

Lysophosphatidic Acid Stimulates Activation of Focal Adhesion Kinase and Paxillin and Promotes Cell Motility, via LPA1-3, in Human Pancreatic Cancer
Researchers examined the involvement of lysophosphatidic acid (LPA)1-3 in LPA-induced activation of focal adhesion kinase and paxillin, and in cell motility, in pancreatic cancer PANC-1 cells. Three LPA receptors were significantly expressed in PANC-1 cells. [Dig Dis Sci] Abstract

Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link?
The authors present an insight on the morphological and molecular aspects of epithelial-mesenchymal transition (EMT) and on the factors that are involved in the induction of EMT in pancreatic ductal adenocarcinoma. [Front Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza® (Saxagliptin) SAVOR Cardiovascular Outcomes Trial
AstraZeneca and Bristol-Myers Squibb Company announced additional results from the SAVOR cardiovascular outcomes trial, which found no increased rate of hypoglycemia among patients treated with Onglyza® compared to placebo when added to metformin monotherapy and higher rates of hypoglycemia only in the Onglyza group compared to the placebo group among patients taking sulfonylureas, agents known to cause hypoglycemia, at baseline. [Press release from AstraZeneca discussing research presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
Invokana® (Canagliflozin) Receives Positive Opinion Recommending Approval in the European Union for the Treatment of Adults with Type 2 Diabetes Mellitus
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use has granted a positive opinion recommending approval of INVOKANA® in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycemic control. [Janssen-Cilag International NV]
Press Release

Leading Pharma Company Selects Clinilabs to Conduct a Phase I Study of an Investigational Type 2 Diabetes Medication
Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus. [Clinilabs Inc.] Press Release

JDRF Honors Researchers Whose Insights on Early Type 1 Diabetes Development Have Set the Stage for Disease Prevention in Children
JDRF awarded three talented scientists its prestigious Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award, recognizing their important contributions toward understanding the natural history and pathogenesis of type 1 diabetes in children. [JDRF] Press Release
US Government Shuts Down
The US government entered a state of suspended animation on 1 October after Congress failed to agree on a budget for the next fiscal year, causing federal agencies – including those overseeing science policy and research – to shut down indefinitely. Most government scientists were ordered to stay at home, their offices and labs closed or run by a skeleton staff of ‘essential’ workers. The National Institutes of Health and the National Science Foundation stopped processing grants, some government websites were made inaccessible and many important research programmes were left hanging, potentially putting lives at risk in the case of some disease studies. [Nature Magazine] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW ACCryo2014: Advances in Thermal Ablative Therapy & Biopreservation
January 15-19, 2014
Key Largo, United States

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Postdoctoral Fellow – Molecular Mechanisms of Cancer Progression (University of South Alabama)

Postdoctoral Position – Cardiovascular Development and Diabetes (Cornell University)

Postdoctoral Researcher – Molecular Mechanisms of Innate Immunity and Inflammation (University of North Carolina at Chapel Hill)

Postdoctoral Researcher – Pancreatic Cancer (UT Southwestern Medical Center at Dallas)

Postdoctoral Fellow – Molecular Mechanisms of Cardiovascular Diseases (University of Rochester Medical Center)

Postdoctoral Position – Mechanism of Pancreatic Beta Cell Proliferation (Joslin Diabetes Center/Harvard Medical School)

Postdoctoral Researcher (The University of Texas Health Science Center at San Antonio)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pancreatic Cell News: Archives | Events | Contact Us